novel compounds of structural formula are disclosed . as modulators of the cannabinoid - 1 receptor , these compounds are useful in the treatment , prevention and suppression of diseases mediated by the cb1 receptor . as such , compounds of the present invention are useful as in the treatment , prevention and suppression of psychosis , memory deficits , cognitive disorders , migraine , neuropathy , neuro - inflammatory disorders , cerebral vascular accidents , head trauma , anxiety disorders , stress , epilepsy , parkinson &# 39 ; s disease , and schizophrenia . the compounds are also useful for the treatment of substance abuse disorders , particularly to opiates , alcohol , and nicotine . the compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith .